Ertugliflozin in VERTIS CV: Cardiovascular Evidence
2026-08-20
The VERTIS CV trial established that ertugliflozin was noninferior to placebo for major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Its event-driven design provides a useful framework for interpreting cardiovascular safety, heart-failure signals, renal outcomes, and the limits of translating clinical findings into mechanistic diabetes mellitus research.
Topotecan: Assay Design from DNA Damage to Imaging
2026-08-19
Topotecan and SKF104864 offer a powerful framework for studying replication-associated DNA damage, apoptosis, and treatment response. This guide adds a distinctive assay-design perspective by connecting Topotecan experiments with lessons from quantitative radiotracer biodistribution research.
Trelagliptin Succinate: Designing Better Assays
2026-08-19
Trelagliptin succinate is more than a long-acting DPP-4 inhibitor for type 2 diabetes research. This article translates its incretin biology and AMPK/SOX-9 chondrocyte evidence into practical, pathway-aware assay design and interpretation.
PBS (Phosphate-Buffered Saline) Workflow Guide
2026-08-18
PBS (Phosphate-Buffered Saline), SKU K2818, provides a sterile, isotonic buffer for cell washing, reagent dilution, and other routine in vitro workflows requiring controlled pH and osmolarity. It is intended for scientific research use only and should not be used for diagnostic, medical, or clinical applications.
Nav1.5 Ser571 Links Aging to Cardiac Dysfunction
2026-08-18
The 2024 reference study identifies Nav1.5 phosphorylation at Ser571 as a mechanistic link between increased late sodium current, delayed ventricular repolarization, and impaired diastolic function during aging. Its combination of age-stratified mouse models, targeted channel mutations, electrocardiography, ventricular mechanics, and pharmacological inhibition provides a framework for studying how late sodium influx contributes to the aging myopathy.
Talabostat Mesylate and Skin Barrier Assays
2026-08-17
Talabostat mesylate (PT-100) is a DPP4/FAP inhibitor commonly studied in tumor immunology. This article presents a distinct assay strategy for testing how extracellular peptidase inhibition may influence epithelial barrier biology while keeping NLRP10 findings mechanistically and translationally separate.
FAPα-Sensitive Nanoparticles for Urinary Tumor Diagnosis
2026-08-16
Feng and colleagues developed magnetic iron oxide nanoparticles carrying a substrate–reporter peptide that is cleaved by tumor-associated FAPα and produces a measurable urinary signal. In an esophageal squamous cell carcinoma xenograft model, the platform combined tumor localization with noninvasive ELISA-based detection, providing a strong proof of concept for synthetic urinary biomarkers.
AO/PI Double Staining Kit: Practical Workflow
2026-08-15
The AO/PI Double Staining Kit provides a rapid fluorescent cell staining workflow for separating viable, apoptotic, and necrotic populations in a single sample. It is suitable for screening cell viability and death-associated changes, but should not be treated as standalone confirmation of apoptosis mechanism or as a substitute for model-specific validation.
GS967: Cardiac Late Sodium Current Workflows
2026-08-15
GS967 is a potent cardiac late sodium current inhibitor for linking abnormal Na⁺ influx with repolarization, calcium handling, relaxation, and arrhythmia phenotypes. This guide presents practical workflows for ventricular myocytes, aging models, isolated hearts, and ischemia-induced arrhythmia studies, with troubleshooting guidance for reproducible results.
Trelagliptin Protects Chondrocytes via AMPK/SOX-9
2026-08-14
The reference study identifies an unreported cartilage-protective activity of trelagliptin in an interleukin-1β model of osteoarthritis-like chondrocyte dysfunction. Its experiments connect reduced inflammation, oxidative stress, and matrix loss to restoration of the AMPK/SOX-9 axis, while also showing why these findings remain preclinical and cell-model specific.
Elobixibat hydrate: Applied IBAT Research Workflows
2026-08-14
Learn how Elobixibat hydrate can be used to interrogate bile acid transport, colonic motility, GLP-1 signaling, and metabolic endpoints in translational research. The guide combines compartment-aware assay design, bowel-focused use cases, and practical troubleshooting for more reproducible ileal bile acid transporter inhibition studies.
Dantrolene Sodium Salt: Calcium-to-CRISPR Insight
2026-08-13
Dantrolene sodium salt is a potent ryanodine receptor antagonist for dissecting intracellular calcium release. This article develops a cautious calcium-to-CRISPR framework that separates direct DNA repair effects from cell-state and viability confounders.
PF-04971729 Workflows for SGLT2 Research
2026-08-13
Ertugliflozin (PF-04971729) enables selective interrogation of renal glucose transport, metabolic phenotypes, and inflammation-linked barrier repair. This practical guide connects concentration-controlled in vitro assays with oral dosing studies while keeping cardiovascular evidence and translational limitations in view.
WZ4003: From NUAK Biology to Assay Design
2026-08-12
WZ4003 is a selective NUAK1/2 inhibitor for connecting kinase target engagement with migration, proliferation, invasion, and tau biology. This guide focuses on assay architecture, model-dependent interpretation, and practical decisions for cancer research and neurodegeneration studies.
HMGCS2 Loss Drives Lipid-Linked Pulmonary Fibrosis
2026-08-12
Yang et al. identify injured alveolar type II epithelial cells as a major source of accumulated lysophosphatidylcholine during experimental pulmonary fibrosis and show that these lipids activate lung fibroblasts. Their mechanistic data connect reduced epithelial HMGCS2 to impaired lipid degradation through a PPARα–CPT1A/CPT2 axis, suggesting an epithelial metabolic target for fibrosis research.
460 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page